Bristol-Myers sales and marketing update

Bristol-Myers said it will offer price concessions for HIV/AIDS drugs Reyataz atazanavir and Sustiva efavirenz as part of state-run AIDS Drug Assistance Programs (ADAPs) in an enhanced agreement made with the ADAP Crisis Task Force (ACTF) of the National Alliance of State & Territorial AIDS Directors (NASTAD). The pharma also said it will offer patients multiple ways to access the drugs at reduced or no cost through its Access Virology program, which includes a patient assistance program, which will provide free HIV drugs to patients based on medical and financial needs, as well as a co-pay benefit program. Bristol-Myers will pay the first $200 per month of a patient's out-of-pocket co-pay costs for up to one year, if eligible, under the co-pay program.

Reyataz is a protease inhibitor. Sustiva is a non-nucleoside reverse transcriptase inhibitor (NNRTI). ...